| Primary |
| Cystic Fibrosis |
26.5% |
| Pseudomonas Infection |
20.5% |
| Anti-infective Therapy |
9.5% |
| Product Used For Unknown Indication |
5.0% |
| Conjunctivitis |
4.0% |
| Postoperative Care |
4.0% |
| Asthma |
3.5% |
| Eye Infection |
3.0% |
| Febrile Neutropenia |
3.0% |
| Sepsis |
3.0% |
| Cardiac Failure |
2.5% |
| Vitamin Supplementation |
2.5% |
| Bronchiectasis |
2.0% |
| Staphylococcal Infection |
2.0% |
| Antiinflammatory Therapy |
1.5% |
| Arthritis Infective |
1.5% |
| Blood Cholesterol Increased |
1.5% |
| Chalazion |
1.5% |
| Cystic Fibrosis Lung |
1.5% |
| Infection |
1.5% |
|
| Renal Failure Acute |
24.7% |
| Tinnitus |
7.1% |
| Drug Ineffective |
5.9% |
| Blood Creatinine Increased |
4.7% |
| Haemorrhage |
4.7% |
| Renal Impairment |
4.7% |
| Renal Tubular Necrosis |
4.7% |
| Vomiting |
4.7% |
| Anaphylactic Reaction |
3.5% |
| Eye Irritation |
3.5% |
| Infective Pulmonary Exacerbation Of Cystic Fibrosis |
3.5% |
| Neuralgic Amyotrophy |
3.5% |
| Ocular Hyperaemia |
3.5% |
| Pseudomonas Infection |
3.5% |
| Staphylococcal Infection |
3.5% |
| Tachypnoea |
3.5% |
| Wheezing |
3.5% |
| Bartter's Syndrome |
2.4% |
| Death |
2.4% |
| Dizziness |
2.4% |
|
| Secondary |
| Pseudomonas Infection |
24.9% |
| Drug Use For Unknown Indication |
21.1% |
| Mycobacterium Abscessus Infection |
11.7% |
| Product Used For Unknown Indication |
11.3% |
| Cystic Fibrosis |
7.7% |
| Gastrooesophageal Reflux Disease |
2.5% |
| Pneumonia |
2.5% |
| Postoperative Care |
1.9% |
| Hypertension |
1.8% |
| Anti-infective Therapy |
1.7% |
| Eye Oedema |
1.7% |
| Blood Cholesterol Increased |
1.6% |
| Staphylococcal Infection |
1.6% |
| Eye Inflammation |
1.3% |
| Eye Operation |
1.2% |
| Type 2 Diabetes Mellitus |
1.2% |
| Antibiotic Prophylaxis |
1.2% |
| Cystic Fibrosis Lung |
1.2% |
| Systemic Antibacterial Therapy |
1.1% |
| Antiinflammatory Therapy |
1.0% |
|
| Weight Decreased |
13.7% |
| Renal Failure Acute |
13.1% |
| Tachycardia |
10.7% |
| Tinnitus |
9.5% |
| Drug Ineffective |
6.5% |
| Renal Tubular Necrosis |
6.5% |
| Drug Hypersensitivity |
3.6% |
| Renal Impairment |
3.6% |
| Clostridium Difficile Colitis |
3.0% |
| Dehydration |
3.0% |
| Hypersensitivity |
3.0% |
| Neuralgic Amyotrophy |
3.0% |
| Sepsis |
3.0% |
| Thrombocytopenia |
3.0% |
| Visual Acuity Reduced |
3.0% |
| Ageusia |
2.4% |
| Antibiotic Level Above Therapeutic |
2.4% |
| Pyrexia |
2.4% |
| Urinary Tract Infection Enterococcal |
2.4% |
| Wheezing |
2.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
42.8% |
| Drug Use For Unknown Indication |
24.8% |
| Prophylaxis |
3.5% |
| Cystic Fibrosis |
3.4% |
| Diffuse Panbronchiolitis |
3.0% |
| Infection Prophylaxis |
2.8% |
| Acute Myeloid Leukaemia |
1.8% |
| Sepsis |
1.8% |
| Pain |
1.7% |
| Pseudomonas Infection |
1.7% |
| Asthma |
1.7% |
| Hypertension |
1.6% |
| Multiple Myeloma |
1.5% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Hiv Infection |
1.3% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Diffuse Large B-cell Lymphoma |
1.0% |
| Pyrexia |
1.0% |
| Depression |
0.9% |
| Pneumonia |
0.9% |
|
| Vomiting |
14.1% |
| Weight Decreased |
12.8% |
| Renal Impairment |
6.4% |
| Sepsis |
6.4% |
| Septic Shock |
5.4% |
| White Blood Cell Count Increased |
5.4% |
| Renal Failure Acute |
4.7% |
| Pyrexia |
4.4% |
| Weight Increased |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Drug Ineffective |
4.0% |
| Pneumonia |
3.7% |
| Respiratory Failure |
3.7% |
| Patent Ductus Arteriosus |
3.4% |
| Tachycardia |
3.4% |
| Urticaria |
3.0% |
| Electrolyte Imbalance |
2.7% |
| International Normalised Ratio Increased |
2.7% |
| Pain |
2.7% |
| Renal Failure |
2.7% |
|
| Interacting |
| Pseudomonas Infection |
47.5% |
| Lung Transplant |
14.8% |
| Antiinflammatory Therapy |
9.8% |
| Inflammation |
9.8% |
| Arthropathy |
4.9% |
| Sedation |
4.9% |
| Respiratory Failure |
3.3% |
| Transplant Evaluation |
3.3% |
| Drug Use For Unknown Indication |
1.6% |
|
| Weight Decreased |
62.5% |
| Renal Failure Acute |
18.8% |
| Troponin I Increased |
18.8% |
|
